A theranostic microneedle array patch for integrated glycemia sensing and self-regulated release of insulin. (2nd February 2022)

• Record Type: Journal Article
• Authors: Sun, Xuetong; Ji, Wenwen; Zhang, Bei; Ma, Lijuan; Fu, Wenjuan; Qian, Wenhui; Zhang, Xiangying; Li, Jianting; Sheng, Enze; Tao, Yi; Zhu, Dong
• Is Part Of: Biomaterials science. Volume 10:Number 5(2022)
• Page Start: 1209
• Page End: 1216
• Publication Date: 2022-02-02
• Subjects: Biomedical materials -- Periodicals; 610.28
• DOI: 10.1039/d1bm01834e
• Languages: English
• ISSNs: 2047-4830

Abstract

Abstract : We have designed a dual-function microneedle patch that integrates treatment and diagnosis. Abstract : Diabetes can cause various complications and affect the normal functioning of the human body. A theranostic and diagnostic platform for real-time glycemia sensing and simultaneous self-regulated release of insulin is desired to improve diabetic patients' life quality. Here, we describe a theranostic microneedle array patch, which enables the achievement of visualization quantification of glycemia and simultaneously self-regulated release of insulin. The microneedle patch (MNDF) was fabricated by crosslinking of 3-aminophenylboronic acid (ABA)-modified sodium alginate and chondroitin sulfate. The hierarchical structure consisted of a tip part containing mineralized insulin particles and glucose oxidase (GOD) for insulin release, and a base surface embodying 3, 3′, 5, 5′-tetramethylbenzidine (TMB) and (horseradish peroxidase) HRP for real-time glycemia sensing. In the presence of glucose, GOD converts glucose into H + and H2 O2, driving gradual dissolution of the calcium layer of insulin particles, resulting in long-acting release of insulin. By the bio-catalytic action of HRP, the generated H2 O2 brings about a visible color change allowing the glucose level at the base surface to be read out. We believe that the theranostic microneedle array patch can act as a promising alternative for future clinical applications.